New Rochelle, NY, September 10, 2018-Researchers have now grown lung organoids from human embryonic stem cells (hESCs) that, after implantation in mice, can develop mature alveolar type 1 (AT1) and AT2 cells and architecture approximating that of human lungs. The strategy is the first to generate both lung distal progenitor cells and mature AT1-like cells. The study is published in Stem Cells and Development, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. Click here to read the full-text article free on the Stem Cells and Development website through October 10, 2018.
Ling Yin, Zhili Rong, and colleagues from the Cancer Research Institute of Southern Medical University, Guangzhou, China, present their research in an article titled "Long-Term Engraftment Promotes Differentiation of Alveolar Epithelial Cells from Human Embryonic Stem Cells Derived Lung Organoids". The authors prepared lung organoids by providing hESCs with a specific set of differentiation-inducing growth factors and chemical inhibitors and then embedding these cells in Matrigel. After different growth periods from ~3-6 weeks, formed organoids were engrafted into immunocompromised mice to assess further differentiation. The authors studied these organoids after short-term (21 d) or long-term (?100 d) engraftment and identified a progression from abundant progenitor cell types to more completely differentiated and mature AT1 and AT2 cells as the duration of in vitro differentiation and engraftment increased, thus providing a model of human lung development.
"Using a relatively inexpensive protocol, the authors demonstrate human lung organoids derived from human pluripotent stem cells can generate mature alveolar type I and II -like cells after four months transplantation in a murine renal capsule model," says Editor-in-Chief Graham C. Parker, PhD, The Carman and Ann Adams Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
About the Journal
Stem Cells and Development is an authoritative peer-reviewed journal published 24 times per year in print and online. The Journal is dedicated to communication and objective analysis of developments in the biology, characteristics, and therapeutic utility of stem cells, especially those of the hematopoietic system. A complete table of contents and free sample issue may be viewed on the Stem Cells and Development website.
About the Publisher
Mary Ann Liebert, Inc., publishers is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cellular Reprogramming, Tissue Engineering, and Human Gene Therapy. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry's most widely read publication worldwide. A complete list of the firm's 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers website.